Agilus Diagnostics, one of India’s largest diagnostic company, has joined forces with Lucence, a global leader in molecular diagnostics, to enhance cancer detection and personalized treatment in India. This partnership will integrate Lucence’s cutting-edge molecular testing technologies into Agilus’ extensive laboratory network, improving cancer diagnosis, treatment selection, and disease monitoring.
Integrating Advanced Molecular Testing Solutions
Through the collaboration, Agilus Diagnostics will incorporate Lucence’s advanced molecular testing solutions into its oncology diagnostics portfolio. A key offering, LiquidHALLMARK®, is an ultra-sensitive liquid biopsy. It uses next-generation sequencing to analyze circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA). This test detects clinically relevant biomarkers across cancers. It profiles 80 ctDNA genes and 37 ctRNA fusions with actionable somatic mutations.
Commitment to Innovation and Precision Medicine
“At Agilus Diagnostics, we are dedicated to advancing diagnostic excellence through innovation and strategic collaborations. Partnering with Lucence strengthens our ability to provide world-class cancer diagnostics, offering oncologists and patients precision-driven solutions,” said Dr. Anand K, Managing Director and CEO of Agilus Diagnostics. India, home to 1.43 billion people, faces a significant cancer burden, with 1.46 million new cases and 916,000 cancer-related deaths annually.
Expanding Access to Liquid Biopsy and Precision Oncology
Lucence’s proprietary technology will enable Agilus Diagnostics to enhance its oncology capabilities. By incorporating liquid biopsy-based screening, the company aims to facilitate early cancer detection, recurrence monitoring, and personalized therapy selection. This collaboration will make precision oncology more accessible across India through Agilus’ vast network of laboratories.
“Lucence is committed to transforming cancer care with non-invasive, highly accurate genomic tests. Our partnership with Agilus Diagnostics allows us to scale our impact and bring precision oncology to a larger patient population in India,” said Tan Min-Han, M.B.B.S., F.R.C.P., Ph.D., founding CEO and medical director of Lucence.
Advancing Cancer Care for Indian Patients
The collaboration aligns with Agilus Diagnostics’ mission to leverage technological advancements in laboratory medicine. As per the press release, Agilus integrates state-of-the-art molecular diagnostics. This ensures Indian patients and healthcare providers access world-class cancer testing and precision medicine solutions.